Homepage

Funding groundbreaking research. Changing lives.

Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.

PROVIDING EDUCATION AND RESOURCES FOR A BETTER TODAY. INVESTING IN RESEARCH FOR A BETTER TOMORROW.

MPNRF By the Numbers

$ 0 MM
MPN RESEARCH FUNDED
0
RESEARCHERS SUPPORTED
0
PROJECTS FUNDED

What is Primary Myelofibrosis (MF)?

Primary Myelofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is Polycythemia Vera (PV)

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Recent News

  • Global Research Impacts Patients Around the World

    MPN NEWS | November 20, 2021

    Earlier this month, we joined our global partners as part of the 6th International MPN Horizons Conference, convening MPN advocates from 33 countries to share the latest research, care standards, and current therapies.  Amongst the rich medical and advocacy content presented, Kapila Viges of MPNRF co-chaired two medical sessions. The first highlighted genetic testing, disease progression,… Read More »Global Research Impacts Patients Around the World

    READ MORE

    The Changing Landscape for Patients

    MPN NEWS | November 18, 2021

    When ruxolitinib (Jakafi®) was approved by the U.S. Food and Drug Administration (FDA) to treat myelofibrosis (MF) ten years ago, it was celebrated as the first treatment specifically for an MPN. Three years later, it was approved to treat polycythemia vera (PV). The landscape for patients is much different now than when ruxolitinib was initially… Read More »The Changing Landscape for Patients

    READ MORE

    3-Year Global MPN Interferon Initiative 

    MPN NEWS | November 1, 2021

    Chicago, IL, November 1, 2021 (Newswire) – In real world usage and in clinical trials, interferon (IFN), in a variety of forms, has shown high rates of hematologic and molecular responses in most patients with polycythemia vera (PV) and essential thrombocythemia (ET), and some patients in the early phase of primary myelofibrosis (PMF), together a… Read More »3-Year Global MPN Interferon Initiative 

    READ MORE
  • Ready to do more?

    Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

    Stay Connected

    With your generous gift, you can change a MPN patient’s prognosis.

    By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.

    DONATE NOW

    Want to learn more about MPNs? Be the first to know about what’s going on in the PV, ET, and MF community.
    Get the MPNRF Newsletter